Using convalescent plasma and monoclonal antibodies to treat COVID-19 in immunocompromised patients
Analysis of the Efficacy and Tolerance of Covid-19 Convalescent Plasma and Monoclonal Antibodies in the Treatment of SARS-Cov2 Infections in Immunocompromised Patients
This study is trying to see if convalescent plasma or monoclonal antibodies can help hospitalized patients with weakened immune systems recover from COVID-19.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT05905380 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data on the effectiveness of convalescent plasma treatment for COVID-19 in immunocompromised patients. It focuses on individuals who have been hospitalized and received either monoclonal antibody treatment or convalescent plasma for SARS-CoV-2 infection. The study seeks to understand the potential benefits of these treatments in patients whose clinical manifestations are primarily due to uncontrolled infection rather than cytokine storms. The research will analyze existing patient data collected from specific hospitals in France over a defined period.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients who are immunocompromised due to conditions such as solid neoplasia, malignant hemopathy, or organ transplantation.
Not a fit: Patients who are not immunocompromised or those who have expressed opposition to the reuse of their data for research purposes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into effective COVID-19 treatments for immunocompromised patients.
How similar studies have performed: While data on convalescent plasma in immunocompetent patients have been disappointing, there is limited evidence suggesting potential benefits in immunocompromised patients, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Adult patient * Immunocompromised patient (solid neoplasia, malignant hemopathy, solid organ transplantation, primary immune deficiency, systemic disease, chronic inflammatory disease, etc.) * Hospitalized between 25/02/2020 and 15/01/2023 at HUS, ICANS, CH Colmar and CH Mulhouse * Having received curative monoclonal antibody treatment or convalescent plasma treatment for SARS-Cov2 infection * Patient who has not expressed, after being informed, his opposition to the reuse of his data for scientific research purposes. Exclusion criteria: * Subject who expressed their opposition to participating in the study * Subject under guardianship, curatorship or safeguard of justice
Where this trial is running
Strasbourg
- Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: François DANION, MD
- Email: Francois.danion@chru-strasbourg.fr
- Phone: 33 3 69 55 15 88
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.